Digital Genome Engineering Market Size and Share is Estimated to Growth by US$ 60.35 at CAGR 11.1% during Forecast period 2028

This press release was orginally distributed by SBWire

Londan, United kingdom (SBWIRE) 06/06/2022 Digital Genome Engineering is a comprehensive digital set of genetic material that occurs in a cell or an organism. It allows experts to get a nearer look at genetic disorders, with instant access to sequence data and tools to resolve unending custom queries. Thus, the aforementioned parameters will augment the market growth. Digital Genome Engineering deals with genes & their functions and assists in finding causes behind chronic disorders and also to resolve them. This technology has sparked a revolt in invention-centred research & systems biology to expedite insight of the most complex genetic systems.

The global Digital Genome Engineering market research report provides an in-depth analysis of the existing and future state of the industry. The study comprises all market data and is based on extensive primary and secondary research. Statistics by type, industry, channel, and other parameters are included in the analysis, as well as market volume and value for each category. The coronavirus pandemic has an influence on the global economy. Several market conditions have shifted. The market is fast evolving, according to the study report, and its influence is being studied both now and in the future.

Get a Sample Report of Digital Genome Engineering Market @ https://www.intelligencemarketreport.com/report-sample/486645

The study offers exact figures for the industry's market size, share, production capacity, demand, and growth for the anticipated year. This is the most recent market effect analysis research for COVID-19. The Digital Genome Engineering market research looks at the market's top businesses, distributors, and the entire structure of the industrial chain. It also evaluates the aspects and criteria that may have an impact on market expansion.

The Major Key Company Profiles included in Digital Genome Engineering market study are:

-Abbott Laboratories-Agilent Technologies Inc-Becton, Dickinson and Company-Biomerieux SA-Bio-rad Laboratories Inc-Roche-Illumina Inc-Inscripta-Oxford Nanopore Technologies Ltd-Pacific Bioscience-Perkinelmer Inc-Qiagen NV-Regeneron Pharmaceuticals-Thermo Fisher Scientific Inc

Market Segmentation

The research looks on the industry's growth goals, cost awareness, and manufacturing procedures. Market segmentation by product type, application, end-user, and geography is discussed in the Digital Genome Engineering research report. A basic industry overview, as well as categorization, definition, and, as a result, the supply and demand chain structure, are included in the market study. Global research includes global marketing data, competitive climate surveys, growth rates, and critical development status information.

Russia-Ukraine War Impact on Digital Genome Engineering Market

The impact of the Russia-Ukraine conflict on the worldwide market is covered in the research study. While tensions between Russia and Ukraine have been increasing for years, the present military action heightens fears of a long-term conflict within Ukraine, as well as market and global economic implications. The market research report covers whether this ongoing conflict is making any of on target market or not.

The Digital Genome Engineering Market Segments and Sub-Segments are Listed Below:

Segmentation by type:

-Miss Target Assessment-Target Efficiency Prediction-Typing Efficiency Prediction-Measurement of Editing Efficiency of Target Genome-Other

Segmentation by application:

-Hospital-Research Institute-Institutions of Higher Learning

Do you have any query regarding this research? Ask your Query @ https://www.intelligencemarketreport.com/send-an-enquiry/486645

Regional Analysis

From production and consumer ratios to market size and market share, import and export ratios, supply and demand, consumer demand ratios, technological advancements, research and development, infrastructure development, economic growth, and a strong market presence in every region, research covers everything. Geographic study will assist players in discovering profitable markets where they may capitalize on fresh opportunities. The Digital Genome Engineering market is divided into five regions: North America, Latin America, Europe, Asia Pacific, and the Rest of the World.

Competitive Outlook

The research report covers financial conditions, global positioning, product portfolios, income and gross profit margins, as well as technology and research breakthroughs. The Digital Genome Engineering market research focuses on the industry's most notable acquisitions, collaborations, and product launches. To provide deeper insights into key players, the study report incorporates modern research approaches such as SWOT and Porter's Five Forces analysis. The study provides a comprehensive assessment of the global competitive climate as well as critical insights into the major competitors and their expansion plans.

Table of Contents Major Key Points

1 Scope of the Report2 Executive Summary3 Digital Genome Engineering Market Size by Player4 Digital Genome Engineering by Regions5 Americas6 APAC7 Europe8 Middle East & Africa9 Market Drivers, Challenges and Trends10 Global Digital Genome Engineering Market Forecast11 Key Players Analysis12 Research Findings and Conclusion

Buy Single User PDF of Digital Genome Engineering Market @ https://www.intelligencemarketreport.com/checkout/486645

About Us:

Intelligence Market Report includes a comprehensive rundown of statistical surveying reports from many distributers around the world. We brag an information base traversing basically every market classification and a much more complete assortment of statistical surveying reports under these classifications and sub-classifications.

Intelligence Market Report offers premium reformist factual looking over, statistical surveying reports, investigation and gauge information for businesses and governments all throughout the planet.

For more information on this press release visit: http://www.sbwire.com/press-releases/digital-genome-engineering-market-size-and-industry-analysis-2022-biotechnology-revolution-to-boom-the-digital-genome-business-with-latest-research-development-1358631.htm

More here:
Digital Genome Engineering Market Size and Industry Analysis 2022 : Biotechnology Revolution to Boom the Digital Genome Business with Latest Research...

The new report on Animal Health Biotechnology Market Report 2022 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2030 offered by Market Research, Inc. includes a comprehensive analysis of the market size, geographical landscape along with the revenue estimation of the industry. In addition, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Animal Health Biotechnology Market.

Biotechnology utilized in animal healthcare dates back to 19th century when the first vaccines were prepared for its use in animals. Considerable progress in the animal health biotechnology took place recently when biotechnology applications were utilized in both detecting and treating various infectious and parasitic diseases of animals.

Click the link to get a Sample Copy of the Report: https://www.marketresearchinc.com/request-sample.php?id=115348

This market study covers and analyzes the potential of the global Animal Health Biotechnology industry, providing geometric information about market dynamics, growth factors, major challenges, PEST analysis and market entry strategy analysis, opportunities and forecasts. One of the major highpoints of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19 on Animal Health Biotechnology market.

Animal Health Biotechnology Market: Competition Landscape

The Animal Health Biotechnology market report includes information on the product presentations, sustainability and prospects of leading player including: Bayer AG, Merck & Co.Inc., Pfizer Inc., Sanofi, Santa Cruz Biotechnology

Animal Health Biotechnology Market: Segmentation

By Types

By Applications

Animal Health Biotechnology Market: Regional Analysis

All the regional segmentation has been studied based on recent and future trends and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Animal Health Biotechnology market report are North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and Latin America.

Key Benefits of the report:

Ask for Discount: https://www.marketresearchinc.com/ask-for-discount.php?id=115348

Major Points Covered in TOC:

Market Summary: It incorporates six sections, research scope, major producers covered, market segments by type, Animal Health Biotechnology market segments by application, study goals, and years considered.

Market Landscape: Here, the global Animal Health Biotechnology Market is dissected, by value, income, deals, and piece of the pie by organization, market rate, cutthroat circumstances landscape, and most recent patterns, consolidation, development, and segments of the overall industry of top organizations.

Profiles of Companies: Here, driving players of the worldwide Animal Health Biotechnology market are considered dependent on deals region, key items, net income, cost, and creation.

Market Status and Outlook by Region: In this segment, the report examines about net edge, deals, income and creation, portion of the overall industry, CAGR and market size by locale. Here, the worldwide Animal Health Biotechnology Market is profoundly examined based on areas and nations like North America, Europe, Asia Pacific, Latin America and the MEA.

Application: This segment of the exploration study shows how extraordinary end-client/application sections add to the worldwide Animal Health Biotechnology Market.

Market Forecast: Production Side: In this piece of the report, the creators have zeroed in on creation and creation esteem conjecture, key makers gauge and creation and creation esteem estimate by type.

Research Findings and Conclusion: This is one of the last segments of the report where the discoveries of the investigators and the finish of the exploration study are given.

Enquiry before buying this premium Report: https://www.marketresearchinc.com/enquiry-before-buying.php?id=115348

Contact Us

Market Research Inc

Author: Kevin

US Address: 51 Yerba Buena Lane, Ground Suite,

Inner Sunset San Francisco, CA 94103, USA

Call Us: +1 (628) 225-1818

Write Us: [emailprotected]

Here is the original post:
Animal Health Biotechnology Market 2022- Analysis and In-Depth Research on Market Size, Trends, Emerging Growth Factors and Forecast To 2030 - Digital...

PDS Biotechnology Co. (NASDAQ:PDSB Get Rating) has been given a consensus rating of Buy by the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $21.20.

Separately, StockNews.com upgraded shares of PDS Biotechnology to a sell rating in a research report on Saturday, April 9th.

NASDAQ:PDSB opened at $5.16 on Monday. The firms 50 day simple moving average is $5.95 and its 200 day simple moving average is $7.99. PDS Biotechnology has a one year low of $4.10 and a one year high of $17.85.

Large investors have recently added to or reduced their stakes in the company. Voloridge Investment Management LLC increased its stake in shares of PDS Biotechnology by 279.2% in the 3rd quarter. Voloridge Investment Management LLC now owns 49,191 shares of the companys stock valued at $733,000 after acquiring an additional 36,219 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $632,000. Cubist Systematic Strategies LLC increased its stake in shares of PDS Biotechnology by 187.0% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 71,618 shares of the companys stock valued at $1,067,000 after acquiring an additional 46,665 shares in the last quarter. Jump Financial LLC bought a new stake in shares of PDS Biotechnology in the 3rd quarter valued at $393,000. Finally, Valeo Financial Advisors LLC increased its stake in shares of PDS Biotechnology by 35.7% in the 4th quarter. Valeo Financial Advisors LLC now owns 21,570 shares of the companys stock valued at $175,000 after acquiring an additional 5,670 shares in the last quarter. Institutional investors own 23.91% of the companys stock.

PDS Biotechnology Company Profile (Get Rating)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

Featured Stories

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
PDS Biotechnology Co. (NASDAQ:PDSB) Given Consensus Recommendation of Buy by Analysts - Defense World

Beyond needless loss of life, the war in Ukraine has caused a trade war that could slash global food production, taking the greatest toll on the poorest of us. The silver lining: this tragic situation may inspire some long-overdue policy reforms.

The world is in a precarious place. Besides the fact that several thousand people have already been killed and millions more displaced, the war in Ukraine has triggered a trade war that could do severe damage to farmers and consumers around the world. A handful of wealthy celebrities have celebrated this development, urging the rest of us to endure skyrocketing gas and food prices if it means putting the screws to Putin, as Stark Trek actorGeorge Takeiso unhelpfully put it.

Comments like that play well on Twitter, but they ignore two important points everybody should recognize. Vladimir Putin wont miss any meals because of the economic measures aimed at Russia, but lots of poor people worldwide will go hungry. If there is an upside to this war, its that the subsequent food price hikes and shortages have exposed the folly of Europesprotectionistanti-GMO policies.

Russia and Ukraineproduce just over30 percent of the worlds wheat. Dozens of developing countries count on those exports to feed themselves, and they could suffer devastating consequences if the war and resulting economic sanctions continue to disrupt global trade.

Retired US Army Colonel Douglas MacGregorrecently pointed outthat the Russian army has so far avoided the center of Ukraine, where most of the countrys crops are grown. Thats important over the long term, though farmers may not be able to plant anything this year. Even if they get crops in the ground, their production will be limited because the seed, fertilizer, fuel, and other inputs they need wont be delivered with Russian troopssurroundinga major port city like Mariupol, where a lot of imported goods enter Ukraine.

This is concerning since the United Nations World Food Program (WFP),which helps combat food insecurity primarily in northern African countries, buys about half its wheat from Ukraine. The WFP will either have to pay higher prices to other wheat exporters or buy less grain, and that could mean millions or potentially tens of millions more people transitioning into food insecurity, University of Saskatchewan agricultural economistStuart Smythtold ACSH during a recent interview.

The situation in Russia could have a similarly troubling impact. A few weeks ago, the country got skittish about the quick pace of its grain exports to neighboring ex-Soviet countries,Reuters reported, and moved to slow it down to protect the domestic food market in the face of external constraints, primarily Western sanctions.

That means higher grain prices globally, but the ensuing trade war will have further effects. Russiahas slashedexports of fertilizers that growers around the world depend on. Brazila major exporter of soybeans, coffee, and sugarwas already having trouble acquiring all the crop nutrients it needed before the war broke out. Exacerbated shortages will likely further inflate the prices of these commodities.

And because Russia is home tolarge mineral depositsfound in few other parts of the world, replacing the countrys fertilizer output could take several years, if its even possible. Argentina, another agricultural powerhouse, hascapped soy and corn exportsto shield its population from higher food prices in response to the fertilizer shortage, economist David Stockman noted last week. Overall, were talking about double-digit increases. As Olivier de Matos, director-general of CropLife Europe,wrote on March 17:

Escalating food prices that are already plaguing consumers around the world look set to get much worse. The United Nations has warned that already record global food costs could increase by a further 22% as the war stifles international trade and decimates future harvests.

Before Russian tanks rolled into Ukraine, The European Union was poised to implement its Farm-To-Fork program, whichaimed tocut pesticide use by 50 percent and commit 25 percent of Europes farmland to organic food production by 2030. This was alwaysa misguided plan; now its a pipe dream, and the EU knows it. Policymakers areworking to relaximport restrictions on transgenic (GMO) crops that farmers need for animal feed, an increase beyond the30 million metric tonsof genetically engineered soy Europe already imports.

This is a positive step in the grand scheme of things, and it may finally push Europe into letting farmers grow the biotech crops its regulators knowpose no riskto human health or the environment. It gives governments an opportunity to take a hard look at the underlying rationale for prohibiting GM crop cultivation in the first place, Smyth added. I think some governments are going to say, That time has passed, and we need to change our policies.

Heres to hoping the EU takes Smyths adviceand that this war comes to an end sooner rather than later.

Cameron English is a writer, editor and co-host of the Science Facts and Fallacies Podcast. Before joining ACSH, he was managing editor at the Genetic Literacy Project, a nonprofit committed to aiding the public, media, and policymakers by promoting science literacy. You can visit Camerons website here

A version of this article was posted at American Council on Science and Health and is used here with permission. You can check out the American Council on Science and Health on Twitter @ACSHorg

Read the original post:
Ukraine war exposes EU's organic obsession and biotechnology rejectionism - Genetic Literacy Project

Institute of Bioinformatics and Applied Biotechnology (IBAB), Biotech Park, Electronics City Phase I, Bengaluru 560 100 has invited applications for admission to the 2 years Master of Science in Biotechnology and Bioinformatics Program 2022-24.

The MSc programme in Biotechnology and Bioinformatics is an interdisciplinary programme that positions one at the cutting edge of basic and applied science, in particular in the research field and a unique dual specialization degree programme that builds competence in both biotechnology and computational biology/ bioinformatics.

Students of this programme are provided extensive training in cell and molecular biology, genome editing, computer science, mathematics, statistics, bioinformatics and so on. Right from the beginning, the faculty ensures that the students get an immersive high quality research experience. They also get several opportunities to meet and interact with high-profile scientists from across the globe. Events such as the annual Kiran Mazumdar-Shaw Lecture series have enabled the visit of a Nobel laureate.

Eligibility: Applicant should hold Bachelors degree in any branch of science/technology/medicine such as Life sciences (zoology, botany, genetics, human biology, general life sciences, ecology, environmental biology), bioinformatics, biotechnology, chemistry, physics, mathematics, statistics, any branch of engineering, pharmaceutical sciences, agriculture, medicine, dentistry, horticulture, forestry and veterinary sciences, with degrees such as BSc, BE, BTech, BPharm, MBBS, BDS and BVSc etc. Applicant should have obtained at least 50% marks overall in Bachelors programme. There is no age bar for applying. Applicants who have had a break in their education or have been working for a few years are also eligible. Indian nationals, NRIs and foreign nationals who have passed the qualifying degree examination outside of India, must submit the Equivalence Certificate issued by the Association of Indian Universities along with their application.

Applicants will be short listed based on a proctored online examination. The details will be intimated later. The entrance test to the MSc in Biotechnology and Bioinformatics (20222024) will cover the subjects Physics, Mathematics, Chemistry, and the Life sciences. The details of the syllabus and pattern will be updated on the web page. Any change in the examination pattern will be intimated to the applicants.

The short listed candidates will be interviewed either in person at IBAB, or in online mode. Candidates will be intimated in due course about the date and mode of interview.A scholarship will be awarded based on the performance of the student each year, and the financial need of the student.

Application can be submitted online through the link available in the Program Notification at Announcements link at https://www.ibab.ac.in/ latest by 7.5.2022.Application fee is Rs. 600/-. Mock test (online, can be taken from anywhere) will be held on 15 May 2022. Entrance Test (online, proctored) will be conducted on 22 May 2022. Personal Interview will be between 06 June-16 June 2022. Course Commences on 18 July 2022. For details, visit https://www.ibab.ac.in/

Visit link:
Master of Science in Biotechnology and Bioinformatics at IBAB Bengaluru - Mathrubhumi English

SUMMARY: Simon Anderson (22) combines advanced physical science and competencies necessary to help people of different backgrounds, capacities, and beliefs.

Simon Anderson is building an Independent Scholars major around disparities in health and healthcare that stem from broader issues of diversity, equity, and inclusion. His major emphasizes coursework in biology and the medical humanities. Simon is also pursuing a degree in Biotechnology, with minors in Honors Interdisciplinary Studies and Pre-Medicine. Simon is a prime example of a Biotech student at JMU--passionate, determined, engaged, and innovative, says Dr. Stephanie Stockwell, past director of the Biotechnology program. By combining a wide array of interests and talents, Simon is paving the way for a lifetime of success and positive impact.

Simon is a graduate of South County High School in Fairfax County, Virginia, where he completed a demanding set of AP courses that nurtured his passions for math, biology, and chemistry. He also participated in the Governors School for Medicine and Health Sciences at Virginia Commonwealth University in the summer of 2017. During this program he worked with other students to examine case studies from three perspectives: Person (in-person interviews with the patient), Scientist (lab tests and results), and Community (implications of the ailment for the surrounding people)before splitting into smaller groups and analyzing a case study from all three perspectives simultaneously. In the area I grew up in, sickness and injury were the main reasons people went to the hospital, not for treatments related to opioid abuse, Simon remembers. But I learned that opioid abuse was also becoming a huge problem. Later, at JMU, he learned about the importance of local and county remote access clinics. Its not just in cities where people lack healthcare services, says Simon. If youre in a rural area you may also not have access.

Simon took a Viral Discovery (ISAT 203) course with ISAT professor Dr. Louise Temple in his freshman semester. In that class, Simon had his first real encounter with laboratory research. Viral Discovery is an exploratory experiential science class designed for incoming freshmen. Students learn about the life cycle and ecology of viruses infecting bacteria, collect soil samples, and practice techniques for isolation and purification of viruses from the soil. Dr. Temple is an expert in bacterial pathogenesis and bacterial virus discovery and genomic analysis. Isolated viruses are visualized in her lab using electron microscopy, and the genomic material is isolated and prepared for nucleic acid sequencing. Dr. Temples class built confidence in my ability to assess a problem and come up with solutions in a setting where theres flexible structure and no right answer, Simon recalls. He wanted to keep on with the work he had invested in phages, and so joined Dr. Temples lab. Simon has learned a number of valuable techniques related to DNA isolation and annotation, and is writing a paper about phages.

More recently, Simon enrolled in Cancer Genetics (BIO 477) with Dr. Tim Bloss, associate professor of biology. The course is cross-listed as a graduate-level course (BIO 577). I really enjoyed learning about how cancer develops and progresses, he says. Learning about molecular malfunctions in cancer helps me think about how I might create and test treatments in the future. Simon notes that Dr. Bloss is gifted at explaining genetics to students at both a basic and advanced level.

Simon is also a teaching assistant for JMUs General Chemistry laboratory courses (CHEM 131L and CHEM 132L). The course is designed to acquaint students with basic procedures and techniques encountered in the chemical laboratory. The experiments illustrate these techniques and supplement lectures. Simon gives instruction to students and assists with in-class procedures. He also digitally comments on students lab plans, data, and reports. It was a difficult, hybrid year of lab instruction due to the COVID pandemic. At first professors filmed experiments in the lab themselves, and then trialed virtual lab simulation software. This spring, Simon and other assistants returned to the labs to teach students. Proper use of pipette filler bulbs is one lesson we teach, notes Simon, People seem to have a lot of trouble with them.

Simon joined Independent Scholars to extend and broaden his undergraduate education. He understood that medical schools want to see students prepare themselves with an education in both science and the humanities. Simon found the Medical Humanities minor in the JMU catalog, and realized that he might build a major around it. Simons major is entitled Social Responsibility in Healthcare. It combines physical science and competencies necessary to help people of different backgrounds, capacities, and beliefs.

I wanted to take more classes across a wider range of subjects, says Simon. The Independent Scholars major made it possible to take a bunch of science courses that built a broader base around medical humanities. Simon hopes that the Independent Scholars major will give him exposure to a little bit of everything:biology, chemistry, bioinformatics, sociology, anthropology, psychology, and philosophy. I am just beginning to realize the connections between everything, he says. I want to understand how my research into biology and chemistry intersects with disparities in healthcare and beyond.

Simon says he likes the Independent Scholars approach to learning: I develop my questions, and then look for courses and experiences that can help me answer those questions. I wanted something different, to choose an area of study where the questions arent well established, or the answers known. Simon has written about the complexities of healthcare for the Independent Scholars e-zine on multiple occasions. In his essays, Simon seeks answers to enduring questions: What does it mean to be a doctor in our globalized world? How do institutions treat people of different backgrounds differently? What is healthy, and who gets to decide what healthy is? What are the impacts of structural and institutional prejudices? he asks. Simon is currently studying and writing about how person-oriented perspectives characterized by a holistic approach to patient management that embraces the physical, psychological, and social aspects of health and disease are becoming essential to undergraduate pre-medical education. His essays may be accessed here.

Independent Scholars students complete a culminating capstone project. Simons project has implications for the mitigation of racial disparities in health. He notes that, despite having roughly equal rates of breast cancer as non-Hispanic white women, African-American women are 40% more likely to die from the disease than white women, experience the highest breast cancer mortality of any racial group, and have an increasing rate of incidence of breast cancer. African American women are also more likely to have hormone-dependent breast cancers, which are deadlier than hormone-independent tumors.

Researchers have shown that delivering the protein HES-1 to hormone-dependent breast cancers has the effect of decreasing a nuclear protein called PCNA (found in dividing cells), which inhibits proliferation of the tumor, explains Simon. Were attempting to show that oxidative stress will prompt production of the GFP encoded behind an hlh-29 promoter to increase green fluorescent protein expression in all cells. If Simons project can provide evidence that oxidative stress is capable of increasing cells levels of proteins like HES-1, then they will have also laid the groundwork for potential clinical applications. One such application could be the induction of localized oxidative stress in tumors in an attempt to stall their proliferation, which would provide other therapies with an opportunity to shrink and kill the cancer.

Simon was a member of JMUs Huber Residential Learning Community (RLC) for freshmen in 2018-2019. The Huber RLC (which no longer operates) required two classes, one in each of the students first semesters. These classes focused on how different fields of medicine coexist, and gave a place for analysis and discussion of the social determinants of health. In the second semester, each student was required to volunteer with health- and education-related services in Rockingham County and Harrisonburg. Simon volunteered with the Virginia Personal Responsibility Education Program Innovative Strategies (VPREIS) project through JMUs Institute for Innovation in Health and Human Services (IIHHS). His volunteer work included working through the units of VPREISs Vision of Youa program for teen sexual and social health education, currently being administered to at-risk youth as part of a randomized controlled study in decreasing teen pregnancy in Virginia. Simon also volunteered at the ECHO (Ecumenical Community Helping Others) food pantry in Springfield, Virginia during the COVID-19 pandemic.

In the summer of 2021, Simon participated in a virtual summer research internship with the Pediatric Oncology Branch of the National Cancer Institute. During the experience, he worked on three projects that identified novel potential molecular targets in neuroblastoma, devised assembly schemes for designing new chimeric antigen receptors, and reviewed transcripts, patient data, and trial design documents for new psychological health programs. He also attended daily interactive seminars on many topics, including pediatric bone and neural cancers, cancer predisposition syndromes, lab mouse genetics, translation of basic science into therapies, and patient advocacy. Outside of the POB, he participated in an immunotherapy journal club, and two workshops on health disparities and social injustice in health research.

Simon also nurtures interests in how things are made. He enjoys watching videos about how the Disney and Universal theme parks create their engineered attractions, and builds models of landmarks and machinery from around the world. In the summer of 2019, Simon taught LEGO Robotics classes to young people in the Fairfax Collegiate Summer Program, based in Herndon.

See the rest here:
Health Disparities Research and Biotechnology - JMU - James Madison University

NEW YORK, April 26, 2022 /PRNewswire/ -- The Insight Partners published latest research study on "Synthetic Biology Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Products (Enzymes, Chassis Organisms, Oligonucleotides, and Xeno-Nucleic Acids), Technology (Measurement & Modeling, Cloning & Sequencing, Genome Engineering, Gene Synthesis, Nanotechnology, and Others), and Application (Medical Applications, Industrial Applications, Food and Agriculture, Environmental Applications, and Others)", the global synthetic biology market is expected to grow from $10.54 Billion in 2021 to $37.85 Billion by 2028; it is estimated to grow at a CAGR of 20.0%from 2021 to 2028.

The_Insight_Partners_Logo

The synthetic biology market growth is driven by the increasing investments in synthetic biology, advancements in biotechnology, and the rising number of start-ups. However, renewed regulations for biotechnology are restricting market growth.

Get Exclusive Access to Sample Pages of Synthetic Biology Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at: https://www.theinsightpartners.com/sample/TIPHE100000960/

Report Coverage

Details

Market Size Value in

US$ 10.54 Billion in 2021

Market Size Value by

US$ 37.85 Billion by 2028

Growth rate

CAGR of 20.0% from 2021 to 2028

Forecast Period

2021-2028

Base Year

2021

No. of Pages

217

No. Tables

111

No. of Charts & Figures

84

Historical data available

Yes

Segments covered

Products, Technology, and Application

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Synthetic Biology Market: Competitive Landscape and Key Developments

In August 2021, New England Biolabs announced the release of its newest loop-mediated is sthermal amplification (LAMP) products: the WarmStart Multi-Purpose LAMP/RT-LAMP 2X Master Mix (with UDG) and the WarmStart Fluorescent LAMP/RT-LAMP Kit (with UDG), which combines the master mix and LAMP fluorescent dye in one convenient kit. The new master mix and kit enable researchers to perform rapid, high-throughput detection of targeted segments of DNA or RNA using various amplification detection methods.

In April 2022, Agilent Technologies Inc. announced the expansion of CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma patients for treatment with Bristol Myers Squibb's PD-1-targeted immunotherapeutic OPDIVO (nivolumab), in combination with fluoropyrimidine and platinum-based chemotherapy or OPDIVO in combination with YERVOY (ipilimumab). These combined treatments provide new hope for patients diagnosed with these cancers.

Story continues

In April 2022, Merck KGaA launched the first-ever antibody to achieve ACT label designation. ZooMAb antibodies received the lowest Environmental Impact Factor (EIF) scores in the chemicals and reagents category.

Place Your Inquiry Before Buying: https://www.theinsightpartners.com/inquiry/TIPHE100000960/

Global synthetic biology market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for synthetic biology. Asia Pacific is expected to account for the fastest global synthetic biology market growth.. Asia-pacific region will have lucrative growth opportunities during the forecast period due to government initiatives taken in the region. For instance, in November 2017, China launched the first synthetic biology association to support the market's growth. This association promotes academic research and communication in synthetic biology; it further enhances the comprehensive competitiveness of the Shenzhen synthetic biology industry and domestic and foreign influence. While, North America has huge market potential, followed by Europe in the overall synthetic biology market, which is attributed to government funds, investments made by the major companies, conferences held for the awareness regarding synthetic biology, technological advancements in the field of genomics, and higher acceptance by the consumers. However, the MEA and SCAM will also show a relatively lower opportunity in the next few years.

Synthetic biology is an emerging concept that has numerous applications in the chemicals, agriculture, pharmaceuticals, and energy industries. Various start-ups offer gene synthesis products/services for biological processes. For example, Benchling provides CAD tools, GenScript offers gene synthesis, Ginkgo Bioworks assists in organism engineering, Transcripts (a bioinformatics company) offers solutions facilitating cloud labs/automation, and Glowee offers consumer products. Further, 56 synthetic biology businesses raised more than US$ 3 billion in equity financing in the first half of 2020, compared to 65 companies raising US$ 1.9 billion during the same period in 2020. The new generation of biopharma businesses uses synthetic biology to improve cell treatment and gene therapy and support early cancer detection. Some synthetic biology firms with the most funding in the first half of 2020 are listed below.

Table 1. Synthetic Biology Firms with Most Funding in First Half of 2020

Company

Description

Funding

Sana Biotechnology

Biotechnology, Health Care, Life Sciences, and Product Research

US$ 700 million

Impossible Foods

Food & Beverage and Nutrition

US$ 500 million

Moderna Therapeutics

Biotechnology, Genetics, Health Care, Medical, and Pharmaceutical

US$ 483 million

Apeel Sciences

Agriculture, AgTech, Biotechnology, and Food Processing

US$ 250 million

Memphis Meats

Food & Beverage and Nutrition

US$ 161 million

Connect With Our Research Analyst On: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100000960

Synthetic Biology Market: Segmental Overview

The synthetic biology market, based on product, is segmented into oligonucleotides, chassis organisms, enzymes, and xeno-nucleic acid. The oligonucleotides segment is likely to hold the largest share of the market in 2021. Moreover, the same segment is anticipated to register the highest CAGR in the market from 2021-2028. This is mainly because of the rising application of oligonucleotides in genetic testing/ assays and forensic sciences. Based on technology, the market is segmented into, gene synthesis, genome engineering, measurement & modeling, cloning & sequencing, nanotechnology, and others. In 2021, the gene synthesis segment is likely to hold the largest share of the market. However, the genome engineering segment is expected to grow in demand at the fastest CAGR of 20.8% from 2021 to 2028. Based on application, the market is segmented into medical applications, industrial applications, environmental applications, food and agriculture, and others. The medical applications segment is further segmented into drug discovery & therapeutics and pharmaceuticals. In 2021, the medical applications segment is likely to hold the largest share of the market. Moreover, the similar segment is expected to witness growth in its demand at the fastest CAGR of 20.8% from 2021 to 2028.

North America synthetic biology market includes consolidated markets for countries such as the US, Canada, and Mexico. In recent years, all the three countries in the region are witnessing a sequential change in the synthetic biology market. By geography, North America held the largest global synthetic biology market share. This largest share can be attributed to government funds, investments made by the major companies, conferences held for awareness regarding synthetic biology, technological advancements in genomics, and higher consumer acceptance. Synthetic biology is a major tool for biological advances, which helps in providing potential for the development of biological weapons. Security issues can be avoided by regulating the biotechnology industry through policy legislation.

Buy Premium Copy of Synthetic Biology Market Size, Share, Revenue, Strategic Insights and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPHE100000960/

The various government initiatives and funding offered are becoming great support for the synthetic biology market to grow in the US. For instance, according to a report by National Center for Biotechnology Information (NCBI), the US government offers approximately US$ 220 million every year toward synthetic biology research and development.

Browse Adjoining Reports:

Synthetic Biology Technology Market Forecast to 2028 - COVID-19 Impact and Global Analysis ByType (Gene Synthesis, Genome Engineering, Sequencing, Bioinformatics, Cloning, Site-Directed Mutagenesis, Microfluidics, Nanotechnology); Application (Medical, Industrial, Food and Agriculture, Others) and Geography.

Oligonucleotide Synthesis Market Forecast to 2027 Global Analysis by Product (Synthesized Oligonucleotides, Reagents, and Equipment), Application (Research, Diagnostics, and Therapeutics), and End User (Academic Research Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, and Other End Users).

Gene Synthesis Market to 2025 - Global Analysis and Forecasts By Products & Services (Services, Consumable, Software), Application (Research & Development Activities, Diagnostics, Therapeutics, Others) End Users (Academic & Research Institutes, Biotech & Pharmaceutical Companies, Diagnostic Laboratories, Others) and Geography.

Genomics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology (Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, and Others), Product & Service (Instruments/Systems, Consumables, and Services), Application (Diagnostics, Drug Discovery and Development, Precision/Personalized Medicine, Agriculture & Animal Research, and Others) and End User (Research Centers, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others).

Molecular Biology Enzymes, Kits, and Reagents Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Enzymes and Kits & Reagents), Application (Epigenetics, Sequencing, Synthetic Biology, Polymerase Chain Reaction, and Other), End User (Biotechnological & Pharmaceutical Companies, Hospitals & Diagnostic Centres, and Academic & Research Institutes), and Geography.

Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (CRISPR, TALEN, Antisense, and Others), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations).

Biohacking Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Sensors, Smart Drugs, Strains, Wearables, Others); Application (Synthetic biology, Genetic engineering, Forensic science, Diagnosis and treatment, Drug testing, Others); End User (Pharmaceutical and biotechnological companies, Forensic laboratories, Others) and Geography.

Enzymatic DNA Synthesis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Custom DNA Synthesis, DNA Library Synthesis); Application (Synthetic Biology, Genetic Engineering, Therapeutic Antibodies, Vaccine Design, Others); End User (Academic and Research Institutes, Biotech and Pharmaceutical Companies, Diagnostic Laboratories, Other) and Geography.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Sameer JoshiE-mail: sales@theinsightpartners.com Phone: +1-646-491-9876Press Release: https://www.theinsightpartners.com/pr/synthetic-biology-market

Cision

View original content:https://www.prnewswire.com/news-releases/synthetic-biology-market-size-worth-37-85-billion-globally-by-2028-at-20-cagr---exclusive-report-by-the-insight-partners-301532833.html

SOURCE The Insight Partners

Read more here:
Synthetic Biology Market Size Worth $37.85 Billion, Globally, by 2028 at 20% CAGR - Exclusive Report by The Insight Partners - Yahoo Finance

Enteric Diseases Laboratory Branch (EDLB) preparing samples for DNA fingerprinting

Recent advancements in biotechnology have immense potential to help address many global problems; climate change, an aging society, food security, energy security, and infectious diseases.

Biotechnology is not to be confused with the closely related field of biosciences. While biosciences refer to all the sciences that study and understand life, biology, and biological organisms, biotechnology refers to the application of the knowledge of biosciences and other technologies to develop tech and commercial products. Biotechnology is the application of innovation to biosciences in a bid to solve real-world medical problems.

Throw Artificial Intelligence into the mix and we suddenly have a really interesting pot of broth. Several AI trends have already proven beneficial to the development of biotechnology. Dr. Nathan S. Bryan, an inventor, biochemist and professor, who made a name for himself as an innovator and pioneer in nitric oxide drug discovery, commercialization, and molecular medicine, offers his insights on these contributions.

Bryan has always held a strong interest in science and medicine and the innovations surrounding it, as signified in his insistence on the commercialization of his nitric oxide discoveries amid strong criticism and even opposition amongst his peers.. His strong entrepreneurial spirit as an academic was strange to many but has led to dozens of patents and product technology that have now generated over half a billion dollars in sales worldwide and an enterprise value of all his companies at over one billion dollars.

He is optimistic that AI has great potential to revolutionize the biotechnology industry if handled right.

Over the last 3 decades we have made tremendous strides in scientific discoveries that have become very impactful in drug development, health, wellness, and beauty, says Bryan.

All this was done mainly without Artificial Intelligence, imagine what we can achieve if the various concerns are handled and we can utilize the great advantage of machine learning to the fullest? Historically it takes an average of 17 years for a new discovery to come to market.Utilizing AI, it can happen much faster.Its a game-changer if I ever saw one.

AI-Generated Comprehensive Protein Map

Earlier this year the biotechnology world was rocked by an announcement by DeepMind, a subsidiary of Googles parent company, Alphabet. DeepMinds claimed to create the most comprehensive map of proteins to date using artificial intelligence.

Every investigation so far suggests that this is exactly what they have done. Before this breakthrough, determining the structure of a protein could only be done by a series of expensive and time-consuming experiments. However, DeepMind showed that relying on Alphafold, its AI software, it could produce accurate predictions of a proteins structure.

This extended the list of protein structures available in the public domain from 180,000, to a whopping 350,000 and everything can be downloaded by scientists for free. Perhaps the most profound part of this is that the list included 98% of all human proteins, which is astounding for scientists and researchers.

Bryan seems certain that this is just the tip of the iceberg for what is attainable. In his own words;

I can now go to the internet and download the most comprehensive list of human proteins ever into a memory stick. Frankly, that is an unexpected deluge of data, that we still dont know how to process, it is like taking us 10 years ahead in research. Its impact will probably not be felt in how people are treated instantly, but in the long run, it would have saved us a lot of years, says Bryan.

He continues, It only goes to show you why a lot of us in the scientific community are excited about the positive possibilities of AI. This is just the tip of the iceberg.Knowing a proteins structure helps us understand its function and how to repair it if an enzyme becomes dysfunctional.Many diseases, including many caused by a deficiency of nitric oxide are due to dysfunctional enzymes.

Open Source AI Platforms

Health care data and other scientific data are an ever-expanding library. The data is often scattered and complicated to arrange in any meaningful way without intense laborious work.

Scientists around the world are researching AI programs that can automate data maintenance and analysis. AI opensource platforms have become the answer to this desire in many ways. Open source platforms like H2O.ai, and DeepMIB have emerged in the last few years to free lab assistants from repetitive tasks such as data entry and analysis.

Bryan expands on the value of AI-open source platforms;

Research is a bigger deal than most people understand. A lot of tasks are heavy and repetitive, yet they have to be done repeatedly with the utmost care because every research failure is a lot of money and energy down the drain. Most basic science discoveries never lead to any effective medicine or therapy because it fails to translate into humans.

Dr. Nathan S. Bryan

He continues, In the science of nitric oxide, which is a gas that when produced is gone in less than a second, it has been very difficult to develop safe and effective therapeutics. We were the first to develop a solid dose of the nitric oxide gas.

Using AI platforms, we can monitor in real time changes in important vital signs and symptoms after administration to demonstrate safety and efficacy. This is really important since nitric oxide cant be measured in clinical labs like cholesterol or Vitamin D. Artificial intelligence is also quicker and more accurate in the analysis of other critical informatics.With the strain of manual labor gone, scientists and healthcare providers alike can focus on innovation.

Intelligent Disease Detection And Diagnosis

A recent study published in the Journal of the National Cancer Institute showed that the use of deep learning has been seen to achieve a breast cancer detection accuracy comparable to an average breast radiologist.

At the end of the day, every scientific sector and indeed every sector in the diverse industries depend on data to run effectively. The ability to organize and classify data into forums and subforums and to predict purported implications is one of the greatest advantages of Artificial Intelligence.

AI and IoT-powered wearables and appliances are another powerful way innovators are using AI to gather health data, in such a way that such data can be used to predict anomalies and early-stage diseases. Loss of nitric oxide is recognized as one of the earliest events in the onset and progression of every major chronic disease. Recognizing this prior to onset of symptoms is key to stopping the progression of disease. This will revolutionize health care and the costs associated with treating patients with advanced disease.

The possibilities are seemingly endless. According to Google, In their latest research, a neural network can be trained to detect signs of lung cancer faster and easier than trained radiologists. Developers are also trying to develop robust AI-driven software that can spot signs of a certain disease accurately in medical images such as, X-rays, MRIs, and CT scans.

Bryan explains, If we can eliminate mistakes in our approach and process, the world would be better for it. This is what I consider the greatest value AI brings. The ability to cross-reference the data of a patient against all other patients with similar diseases and to point out a single disimilarity can be the difference between losing a life and saving it.

What Does The Future Hold?

A lot of things have been touted. If algorithms can process all the information about our health, lifestyle, and the environment we live in, they can give suggestions on what to do to course-correct or to live healthier and hence make us live longer.

AI systems can help us stay fit, it can lighten the workload for doctors, reduce the workload for researchers and simplify the decision-making process. Its greatest contribution would be the ability to understand the vast amounts of scientific data that we have garnered from millennia of study and treatment. It is truly an exciting road of possibilities if we clear all the hurdles.

Bryan explains it well when he says; If we can deal with obstacles like biased data, extreme commercialization of AI systems, there is no way this would not be the catalyst for explosive scientific discoveries and more importantly translation of these discoveries into safe and effective therapeutics in this decade and beyond

As AI makes its journey from the periphery of sciences and healthcare to the mainstream, it seems that all we can do is marvel at the evolution and stand guard as well so that it doesn't become a double edged sword.

Link:
Artificial Intelligence Is Transforming Biotechnology, Especially When It Comes To Innovations In Nitric Oxide - Forbes

Food biotechnology is the field of biotechnology, which is used to modify genes of animals, plants, and microorganisms to create genetically modified products having high nutrition related properties. Genetically advanced products have benefitted farmers, producers, and consumers by increasing their yield and improving the quality of crops, which in turn is expected to drive the market.

Food Biotechnology Market report focused on the comprehensive analysis of current and future prospects of the Food Biotechnology industry. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements for the Food Biotechnology market has been done in order to calculate the growth rates for each segment and sub-segments.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=487977

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Vendors of this Market are:

BASF Plant Science, KWS Group, AquaBounty Technologies, Friesland Campina, DuPont Pioneer, Iden Biotechnology, NovaBiotics, Syngenta AG, Dow AgroSciences LLC, Bayer CropScience AG, Monsanto, Origin Agritech Limited, Camson Bio Technologies Ltd, Arcadia Biosciences, Carbios, BDF Ingredients Zuchem, Evogene Ltd.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Food Biotechnology market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Food Biotechnology markets trajectory between forecast periods.

Global Food Biotechnology Market Segmentation:

Market Segmentation by type: Transgenic Crops, Synthetic Biology Derived Products

Market Segmentation by Application: Animals, Plants, Other

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Food Biotechnology market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Food Biotechnology market.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=487977

The cost analysis of the Global Food Biotechnology Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Reasons for buying this report:

Table of Contents

Global Food Biotechnology Market Research Report 2021 2027

Chapter 1 Food Biotechnology Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Food Biotechnology Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=487977

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Food Biotechnology, Food Biotechnology market, Food Biotechnology Market 2020, Food Biotechnology Market insights, Food Biotechnology market research, Food Biotechnology market report, Food Biotechnology Market Research report, Food Biotechnology Market research study, Food Biotechnology Industry, Food Biotechnology Market comprehensive report, Food Biotechnology Market opportunities, Food Biotechnology market analysis, Food Biotechnology market forecast, Food Biotechnology market strategy, Food Biotechnology market growth, Food Biotechnology Market Analysis in Developed Countries, Food Biotechnology Market by Application, Food Biotechnology Market by Type, Food Biotechnology Market Development, Food Biotechnology Market Evolving Opportunities With Top Industry Experts, Food Biotechnology Market Forecast to 2025, Food Biotechnology Market Future Innovation, Food Biotechnology Market Future Trends, Food Biotechnology Market Google News, Food Biotechnology Market Growing Demand and Growth Opportunity, Food Biotechnology Market in Asia, Food Biotechnology Market in Australia, Food Biotechnology Market in Europe, Food Biotechnology Market in France, Food Biotechnology Market in Germany, Food Biotechnology Market in Key Countries, Food Biotechnology Market in United Kingdom, Food Biotechnology Market is Booming, Food Biotechnology Market is Emerging Industry in Developing Countries, Food Biotechnology Market Latest Report, Food Biotechnology Market Food Biotechnology Market Rising Trends, Food Biotechnology Market Size in United States, Food Biotechnology Market SWOT Analysis, Food Biotechnology Market Updates, Food Biotechnology Market in United States, Food Biotechnology Market in Canada, Food Biotechnology Market in Israel, Food Biotechnology Market in Korea, Food Biotechnology Market in Japan, Food Biotechnology Market Forecast to 2026, Food Biotechnology Market Forecast to 2027, Food Biotechnology Market comprehensive analysis, COVID 19 impact on Food Biotechnology market, BASF Plant Science, KWS Group, AquaBounty Technologies, Friesland Campina, DuPont Pioneer, Iden Biotechnology, NovaBiotics, Syngenta AG, Dow AgroSciences LLC, Bayer CropScience AG, Monsanto, Origin Agritech Limited, Camson Bio Technologies Ltd, Arcadia Biosciences, Carbios, BDF Ingredients Zuchem, Evogene Ltd

More:
Food Biotechnology Market will touch New Level in Upcoming Year | BASF Plant Science, KWS Group, AquaBounty Technologies, Friesland Campina, DuPont...

PDS Biotechnology Corp (PDSB) is near the top in its industry group according to InvestorsObserver. PDSB gets an overall rating of 73. That means it scores higher than 73 percent of stocks. PDS Biotechnology Corp gets a 88 rank in the Biotechnology industry. Biotechnology is number 18 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

PDS Biotechnology Corp (PDSB) stock has risen 1.76% while the S&P 500 has fallen -0.2% as of 11:44 AM on Wednesday, Feb 10. PDSB is higher by $0.12 from the previous closing price of $6.81 on volume of 3,147,508 shares. Over the past year the S&P 500 is up 16.26% while PDSB is higher by 289.33%. PDSB lost -$1.57 per share the over the last 12 months.

Click Here to get the full Stock Score Report on PDS Biotechnology Corp (PDSB) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the rest here:
Is PDS Biotechnology Corp (PDSB) a Winner in the Biotechnology Industry? - InvestorsObserver

A rating of 88 puts Prothena Corporation PLC (PRTA) near the top of the Biotechnology industry according to InvestorsObserver. Prothena Corporation PLC's score of 88 means it scores higher than 88% of stocks in the industry. Prothena Corporation PLC also received an overall rating of 73, putting it above 73% of all stocks. Biotechnology is ranked 16 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 73 means the stock is more attractive than 73 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Prothena Corporation PLC (PRTA) stock has gained 16.88% while the S&P 500 is down 0% as of 10:19 AM on Friday, Feb 12. PRTA is up $2.65 from the previous closing price of $15.70 on volume of 238,634 shares. Over the past year the S&P 500 has risen 16.07% while PRTA is up 42.03%. PRTA lost -$2.78 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Prothena Corporation PLC (PRTA) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See more here:
Is Prothena Corporation PLC (PRTA) a Winner in the Biotechnology Industry? - InvestorsObserver

Xeris Pharmaceuticals Inc (XERS) is near the top in its industry group according to InvestorsObserver. XERS gets an overall rating of 78. That means it scores higher than 78 percent of stocks. Xeris Pharmaceuticals Inc gets a 92 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 78 would rank higher than 78 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Xeris Pharmaceuticals Inc (XERS) stock has gained 7.47% while the S&P 500 has fallen 0% as of 10:19 AM on Friday, Feb 12. XERS is higher by $0.49 from the previous closing price of $6.63 on volume of 4,496,742 shares. Over the past year the S&P 500 is up 16.07% while XERS is higher by 72.64%. XERS lost -$3.10 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Xeris Pharmaceuticals Inc (XERS) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original here:
Is Xeris Pharmaceuticals Inc (XERS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The 45 rating InvestorsObserver gives to Alkermes Plc (ALKS) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 42 percent of stocks in the Biotechnology industry, ALKSs 45 overall rating means the stock scores better than 45 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Alkermes Plc (ALKS) stock is trading at $20.53 as of 1:38 PM on Friday, Feb 12, a gain of $0.51, or 2.55% from the previous closing price of $20.02. The stock has traded between $19.93 and $20.72 so far today. Volume today is less active than usual. So far 974,622 shares have traded compared to average volume of 1,486,778 shares.

Click Here to get the full Stock Score Report on Alkermes Plc (ALKS) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Original post:
Is Alkermes Plc (ALKS) a Winner in the Biotechnology Industry? - InvestorsObserver

Corcept Therapeutics Incorporated (CORT) is near the middle in its industry group according to InvestorsObserver. CORT gets an overall rating of 37. That means it scores higher than 37 percent of stocks. Corcept Therapeutics Incorporated gets a 50 rank in the Biotechnology industry. Biotechnology is number 110 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Corcept Therapeutics Incorporated (CORT) stock is trading at $21.51 as of 10:00 AM on Tuesday, Jun 22, a decline of -$1.47, or -6.4% from the previous closing price of $22.98. The stock has traded between $21.11 and $21.76 so far today. Volume today is light. So far 151,745 shares have traded compared to average volume of 632,416 shares.

Click Here to get the full Stock Score Report on Corcept Therapeutics Incorporated (CORT) Stock.

Visit link:
Is Corcept Therapeutics Incorporated (CORT) a Good Choice in Biotechnology Tuesday? - InvestorsObserver

LONDON, April 21, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Companys research report on the biotechnology services market, the biotechnology services market is expected to grow rapidly due to increasing lifestyle and chronic diseases. This is mainly due to unhealthy lifestyles, a growing aging population, rising inactivity and obesity. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally by the year 2020. China and India together had about 193.4 million diabetic patients in 2019, and India is expected to have about 101 million diabetic patients by 2030. In the field of mental health, the World Health Organization predicts that one in every four people will beaffected by a type of mental disorder such as depression, schizophrenia, or anxiety in the future. In response to this, national governments across the globe are rapidly increasing their medical research expenditure. The world's population is also growing older with every passing year.

For instance, worldwide, the average life expectancy is expected to rise from 73 years to 74.1 years between 2016 and 2021. Based on this estimate, 11.5% of the world population will be over 65 years of age by 2021. Additionally, due to the increased consumption of processed foods, chronic health conditions like diabetes are expected to become more common. Therefore, increasing investment in medical research to treat chronic diseases is further driving the demand for biotechnology services.

The global biotechnology services market is expected to grow from $129.14 billion in 2021 to $151.10 billion in 2022 at a compound annual growth rate (CAGR) of 17.0%. The growth in the market is mainly due to companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. TBRCs biotechnology services market growth analysis states that the market is expected to reach $267.29 billion in 2026 at a CAGR of 15.3%.

Request for a sample of the global biotechnology services market report

The development of automated solutions for devices and equipment is gaining popularity among biotechnology services market trends. Automation of the process will help to enhance productivity and consistency of the whole diagnostic process, along with reducing contact points for samples, consumables, and liquid handling, which improves the safety of clinical and laboratory personnel. In 2019, Thermo Fisher Scientific, based in Massachusetts, USA, a major player in the market, introduced a new benchtop automated reading and incubation system for antimicrobial susceptibility testing (AST). This new instrument will provide microbiology laboratories with accurate minimum inhibitory concentration (MIC) results that are needed by clinicians to confidently select an effective antibiotic for critically ill patients while safeguarding future patient care through more successful antimicrobial stewardship.

Major players in the biotechnology services market are Novartis, Fisher BioService, Pfizer, Novo Nordisk, BioAlps, Precision for Medicine, Sartorius and Aldevron.

The global biotechnology services market segmentation is categorized by service into prevention and disease control, public engagement activities, health education and research, food biotechnology services, donor recruitment, tissue collection, cell processing and isolation, research and development; by industry into Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), Contract Research and Manufacturing Services (CRAMS); by area of application into pharmaceutical, biotechnological, academic, clinical trial, healthcare sectors.

As per the biotechnology services industry overview, in 2021, Asia Pacific was the largest region in the market. North America was the second largest region in the biotechnology services market. The regions covered in the biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Biotechnology Services Global Market Report 2022 Market Size, Trends, And Global Forecast 2022 2026 is one of a series of new reports from The Business Research Company that provide biotechnology services market overviews,biotechnology services market analyze and forecast market size and growth for the whole market, biotechnology services market segments and geographies,biotechnology services market trends, biotechnology services market drivers,biotechnology services market restraints,biotechnology services market leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.

The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Not the market you are looking for? Check out some similar market intelligence reports:

Diabetes Care Devices Global Market Report 2022 By Type (Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters), By End User (Hospitals And Clinics, Diagnostic Laboratories, Other End Users), By Type Of Expenditure (Public, Private), By Product (Instruments/Equipment, Disposables) Market Size, Trends, And Global Forecast 2022-2026

Biosimulation Global Market Report 2022 By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End User (Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CROs), Regulatory Authorities, Academic Research Institutions) Market Size, Trends, And Global Forecast 2022-2026

Laboratory Automation Systems Global Market Report 2022 By Equipment & Software (Automated Liquid Handling, Microplate Readers, Standalone Robots, Automated Storage And Retrieval Systems, Software And Informatics, Other Equipment), By Application (Drug Discovery, Clinical Diagnostics, Genomics Solutions, Proteomics Solutions, Other Applications), By End User (Biotechnology And Pharmaceutical Industries, Research Institutes, Hospitals And Private Labs, Academic Institutes), By Type (Modular Automation, Total Lab Automation) Market Size, Trends, And Global Forecast 2022-2026

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Read the rest here:
The Biotechnology Services Market Is Expected To Reach $267 Billion By 2026 Due To A Rapid Increase In Lifestyle And Chronic Diseases As Per The...

Artelo Biosciences Inc (ARTL) is around the top of the Biotechnology industry according to InvestorsObserver. ARTL received an overall rating of 73, which means that it scores higher than 73 percent of all stocks. Artelo Biosciences Inc also achieved a score of 89 in the Biotechnology industry, putting it above 89 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Artelo Biosciences Inc (ARTL) stock is trading at $3.06 as of 10:19 AM on Friday, Feb 12, a gain of $1.43, or 87.73% from the previous closing price of $1.63. The stock has traded between $2.62 and $3.67 so far today. Volume today is elevated. So far 111,532,303 shares have traded compared to average volume of 7,246,523 shares.

Click Here to get the full Stock Score Report on Artelo Biosciences Inc (ARTL) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Link:
Is Artelo Biosciences Inc (ARTL) the Top Pick in the Biotechnology Industry? - InvestorsObserver

PDS Biotechnology Corp (PDSB) is the highest overall rated company in the Biotechnology industry with an overall score of 91. PDSB is up 734.78% so far this year after the company closed yesterday at $11.52. The overall score measures the company's performance based-off both short and long term indicators and means that PDSB scores better than 91% of the overall market.

PDS Biotechnology Corp is a strong performer in the Biotechnology industry, which has an average overall score of 37. This means that, on average, the stocks in this industry score higher than 37% of the stock market.

To see InvestorsObserver's Sentiment Score for PDS Biotechnology Corp click here.

PDSB has been trading bullishly recently. The stock is trading down -10.42% this week following yesterday's decline. PDSB has an average analyst ranking of Strong Buy with an average price target of $19.25.

Click Here to get the full Stock Score Report on PDS Biotechnology Corp (PDSB) Stock.

See original here:
Is PDS Biotechnology Corp (PDSB) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Arcturus Therapeutics Holdings Inc (ARCT) is around the top of the Biotechnology industry according to InvestorsObserver. ARCT received an overall rating of 50, which means that it scores higher than 50 percent of all stocks. Arcturus Therapeutics Holdings Inc also achieved a score of 82 in the Biotechnology industry, putting it above 82 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 50 would rank higher than 50 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Arcturus Therapeutics Holdings Inc (ARCT) stock is down -7.87% while the S&P 500 has gained 0.56% as of 9:53 AM on Monday, Jun 21. ARCT is down -$2.76 from the previous closing price of $35.09 on volume of 100,649 shares. Over the past year the S&P 500 is higher by 34.39% while ARCT is down -20.57%. ARCT lost -$4.86 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Arcturus Therapeutics Holdings Inc (ARCT) Stock.

Original post:
Where Does Arcturus Therapeutics Holdings Inc (ARCT) Stock Fall in the Biotechnology Field After It Is Down -9.97% This Week? - InvestorsObserver

The market has been high on Cellect Biotechnology Ltd - ADR (APOP) stock recently. APOP gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

Cellect Biotechnology Ltd - ADR (APOP) stock is trading at $4.17 as of 12:27 PM on Thursday, Feb 11, a decline of -$0.58, or -12.19% from the previous closing price of $4.75. The stock has traded between $3.92 and $4.70 so far today. Volume today is elevated. So far 667,963 shares have traded compared to average volume of 237,549 shares.

To see InvestorsObserver's Sentiment Score for Cellect Biotechnology Ltd - ADR click here.

Cellect Biotechnology Ltd is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies. The company is developing its first product based on its ApoGraft technology platform, the ApoTainer kit that utilizes FasL- apoptotic protein.

Click Here to get the full Stock Score Report on Cellect Biotechnology Ltd - ADR (APOP) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Excerpt from:
Is Cellect Biotechnology Ltd - ADR (APOP) a Stock to Watch This Week? - InvestorsObserver

In recent years, however, producers of grapefruit-flavored foods and drinks have not had it easy. Figures from the US Department of Agriculture tell the tale: In the winter of 199697, Florida farmers harvested 59 million boxes of grapefruit. This season, the forecast is for a mere 4.6 million boxes.

Worldwide, the production of grapefruit and other citrus is in peril because of the spread of the citrus greening disease, as well as temperature shifts and extreme weather caused by climate change. Meanwhile, demand for natural citrus flavoring has gone through the roof.

Marifaith Hackett, director of specialty chemicals for the consulting firm IHS Markit: When ingredients come out of by-products of something else, there is always the danger that supply and demand are really out of whack. If you are a purchasing manager, youre likely thinking, We just have to come up with something better.

In the flavor and fragrance industry, that something better may be a manufacturing platform based on fermentation using modified microbes.

Top flavor and fragrance companies have been quietly partnering with biotechnology firms for as long as 2 decades. Recently, their interest has become more public, thanks to acquisitions and in-house investments by firms such as BASF, Firmenich, Givaudan, and Takasago International. And biotech entrants, including Conagen and Manus Bio, are at work expanding the list of available molecules.

Click here to read the full article.

Photo source: Dreamstime.com

Originally posted here:
Flavor and fragrance industries are embracing biotechnology - FreshPlaza.com